Betamab ApS: Financial statements 2020
CVR: 40337326
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
Betamab ApS (CVR 40337326) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -736,481 and a net result of DKK -1,363,690. Equity in the 2020 report amounted to DKK 418,926. The solvency ratio was 56.5%. The company had 2 employees in the financial year.
- Gross Profit
- DKK -736,481
- Profit/Loss
- DKK -1,363,690
- Equity
- DKK 418,926
- Total Assets
- DKK 740,967
- Employees
- 2
Official annual report
How creditworthy is Betamab ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Betamab ApS has published its interim report for the period March 11, 2019 to December 31, 2019.
As of June 30, 2020, 18. juni 2024 P/S has been appointed auditor of Betamab ApS.
As of March 31, 2020, Søren Mouritsen has joined the board of directors of Betamab ApS.
As of March 31, 2020, Morten Peter Meldal has joined the board of directors of Betamab ApS.
As of March 31, 2020, Teit Eliot Johansen is registered as chairman of Betamab ApS.
About Betamab ApS
Betamab ApS was a Danish company of the type Anpartsselskab based in Humlebæk, founded in 2019. The company has been dissolved on 17 May 2022. The company was registered under the industry Forskning og eksperimentel udvikling indenfor bioteknologi. The company has 2 employees (2020). In 2020, the company reported a gross profit of DKK -736,481 and a net result of DKK -1,363,690. Equity in the 2020 report amounted to DKK 418,926.